192 related articles for article (PubMed ID: 21602702)
1. Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes.
Bell LN; Molleston JP; Morton MJ; Klipsch A; Saxena R; Vuppalanchi R; Chalasani N
J Clin Gastroenterol; 2011 Oct; 45(9):800-7. PubMed ID: 21602702
[TBL] [Abstract][Full Text] [Related]
2. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.
Bell LN; Temm CJ; Saxena R; Vuppalanchi R; Schauer P; Rabinovitz M; Krasinskas A; Chalasani N; Mattar SG
Ann Surg; 2010 Jun; 251(6):1041-8. PubMed ID: 20485142
[TBL] [Abstract][Full Text] [Related]
3. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.
Weltman MD; Farrell GC; Hall P; Ingelman-Sundberg M; Liddle C
Hepatology; 1998 Jan; 27(1):128-33. PubMed ID: 9425928
[TBL] [Abstract][Full Text] [Related]
4. Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease.
Prompila N; Wittayalertpanya S; Komolmit P
J Med Assoc Thai; 2008 May; 91(5):733-8. PubMed ID: 18672640
[TBL] [Abstract][Full Text] [Related]
5. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis.
Abdelmegeed MA; Banerjee A; Jang S; Yoo SH; Yun JW; Gonzalez FJ; Keshavarzian A; Song BJ
Free Radic Biol Med; 2013 Dec; 65():1238-1245. PubMed ID: 24064383
[TBL] [Abstract][Full Text] [Related]
6. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.
Leclercq IA; Farrell GC; Field J; Bell DR; Gonzalez FJ; Robertson GR
J Clin Invest; 2000 Apr; 105(8):1067-75. PubMed ID: 10772651
[TBL] [Abstract][Full Text] [Related]
7. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis.
Chtioui H; Semela D; Ledermann M; Zimmermann A; Dufour JF
Liver Int; 2007 Aug; 27(6):764-71. PubMed ID: 17617119
[TBL] [Abstract][Full Text] [Related]
8. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis.
Chalasani N; Gorski JC; Asghar MS; Asghar A; Foresman B; Hall SD; Crabb DW
Hepatology; 2003 Mar; 37(3):544-50. PubMed ID: 12601351
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.
Aubert J; Begriche K; Knockaert L; Robin MA; Fromenty B
Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):630-7. PubMed ID: 21664213
[TBL] [Abstract][Full Text] [Related]
10. TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
Ma HL; Chen SD; Zheng KI; Yu Y; Wang XX; Tang LJ; Li G; Rios RS; Huang OY; Zheng XY; Xu RA; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
J Gastroenterol Hepatol; 2021 Oct; 36(10):2925-2934. PubMed ID: 34031913
[TBL] [Abstract][Full Text] [Related]
11. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women.
Varela NM; Quiñones LA; Orellana M; Poniachik J; Csendes A; Smok G; Rodrigo R; Cáceres DD; Videla LA
Biol Res; 2008; 41(1):81-92. PubMed ID: 18769766
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
Surapaneni KM; Priya VV; Mallika J
Eur Rev Med Pharmacol Sci; 2014; 18(18):2736-41. PubMed ID: 25317811
[TBL] [Abstract][Full Text] [Related]
13. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis.
Abdelmegeed MA; Banerjee A; Yoo SH; Jang S; Gonzalez FJ; Song BJ
J Hepatol; 2012 Oct; 57(4):860-6. PubMed ID: 22668639
[TBL] [Abstract][Full Text] [Related]
14. NKT cell modulates NAFLD potentiation of metabolic oxidative stress-induced mesangial cell activation and proximal tubular toxicity.
Alhasson F; Dattaroy D; Das S; Chandrashekaran V; Seth RK; Schnellmann RG; Chatterjee S
Am J Physiol Renal Physiol; 2016 Jan; 310(1):F85-F101. PubMed ID: 26447219
[TBL] [Abstract][Full Text] [Related]
15. Relevance of CYP2E1 to non-alcoholic fatty liver disease.
Daly AK
Subcell Biochem; 2013; 67():165-75. PubMed ID: 23400921
[TBL] [Abstract][Full Text] [Related]
16. Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.
Abdelmegeed MA; Ha SK; Choi Y; Akbar M; Song BJ
Curr Mol Pharmacol; 2017; 10(3):207-225. PubMed ID: 26278393
[TBL] [Abstract][Full Text] [Related]
17. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
Emery MG; Fisher JM; Chien JY; Kharasch ED; Dellinger EP; Kowdley KV; Thummel KE
Hepatology; 2003 Aug; 38(2):428-35. PubMed ID: 12883487
[TBL] [Abstract][Full Text] [Related]
18. Total sesquiterpene glycosides from Loquat (Eriobotrya japonica) leaf alleviate high-fat diet induced non-alcoholic fatty liver disease through cytochrome P450 2E1 inhibition.
Jian T; Ao X; Wu Y; Lv H; Ma L; Zhao L; Tong B; Ren B; Chen J; Li W
Biomed Pharmacother; 2017 Jul; 91():229-237. PubMed ID: 28458161
[TBL] [Abstract][Full Text] [Related]
19. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.
Brunt EM; Kleiner DE; Wilson LA; Unalp A; Behling CE; Lavine JE; Neuschwander-Tetri BA;
Hepatology; 2009 Mar; 49(3):809-20. PubMed ID: 19142989
[TBL] [Abstract][Full Text] [Related]
20. Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver.
Gopal T; Kumar N; Perriotte-Olson C; Casey CA; Donohue TM; Harris EN; Talmon G; Kabanov AV; Saraswathi V
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G428-G438. PubMed ID: 31928222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
